{"success":true,"data":{"pressRelease":{"id":"159825","rtpr_id":"nACScqQPya-20261003","ticker":"GUTS","exchange":"NASDAQ","all_tickers":["GUTS"],"title":"GUTS ALERT: Securities Fraud Class Action Launched Against Fractyl Health, Inc. – October 20, 2026 Deadline","author":"ACCESSWIRE","published_at":"2026-10-03T22:50:00.779Z","article_body":"NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / October 3,\n2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit\nhas been filed on behalf of investors who purchased or otherwise acquired\nFractyl Health, Inc. (NASDAQ:GUTS) securities.\n\nIf you suffered a loss on your Fractyl Health, Inc. investment and would like\nto explore a potential recovery under the federal securities laws, Learn about\nFractyl Health, Inc. Class Action (https://pr.report/s150) or contact Joseph\nE. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to\nspeak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Fractyl\nHealth, Inc. that seeks to recover losses of shareholders who were adversely\naffected by alleged securities fraud between January 13, 2025 and January 29,\n2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (i) Revita was less effective than\ndefendants had led investors to believe, and/or operational issues at one or\nmore of the REMAIN-1 Midpoint Cohort's clinical sites compromised the\nintegrity of its efficacy results; (ii) accordingly, Revita's clinical,\nregulatory, and commercial prospects were overstated, as was the REMAIN-1\nMidpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result,\ndefendants' public statements were materially false and misleading at all\nrelevant times.\n\nWHAT'S NEXT? If you purchased Fractyl Health, Inc. stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/s151). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/guts-alert-securities-fraud-class-action-launched-against-fracty-1232504)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACScqQPya-20261003","title":"GUTS ALERT: Securities Fraud Class Action Launched Against Fractyl Health, Inc. – October 20, 2026 Deadline","author":"ACCESSWIRE","ticker":"GUTS","created":"2026-10-03T22:50:00.779Z","tickers":["GUTS"],"exchange":"NASDAQ","article_body":"NEW YORK, NY / ACCESS Newswire (https://www.accessnewswire.com/) / October 3,\n2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit\nhas been filed on behalf of investors who purchased or otherwise acquired\nFractyl Health, Inc. (NASDAQ:GUTS) securities.\n\nIf you suffered a loss on your Fractyl Health, Inc. investment and would like\nto explore a potential recovery under the federal securities laws, Learn about\nFractyl Health, Inc. Class Action (https://pr.report/s150) or contact Joseph\nE. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to\nspeak to our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Fractyl\nHealth, Inc. that seeks to recover losses of shareholders who were adversely\naffected by alleged securities fraud between January 13, 2025 and January 29,\n2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: (i) Revita was less effective than\ndefendants had led investors to believe, and/or operational issues at one or\nmore of the REMAIN-1 Midpoint Cohort's clinical sites compromised the\nintegrity of its efficacy results; (ii) accordingly, Revita's clinical,\nregulatory, and commercial prospects were overstated, as was the REMAIN-1\nMidpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result,\ndefendants' public statements were materially false and misleading at all\nrelevant times.\n\nWHAT'S NEXT? If you purchased Fractyl Health, Inc. stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/s151). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/guts-alert-securities-fraud-class-action-launched-against-fracty-1232504)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-03T22:50:00.830302Z","server_sent_at_ms":1791067800830},"received_at":"2026-10-03T22:50:00.881Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/guts-alert-securities-fraud-class-action-launched-against-fracty-1232504"},"analysis":{"id":"148416","press_release_id":"159825","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["alleged securities fraud regarding Revita clinical data and REMAIN-1 trial site integrity","class period spans over a year of company statements"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced a securities fraud class action filed against Fractyl Health on behalf of investors who purchased GUTS securities between January 13, 2025 and January 29, 2026.\n\nThe complaint alleges defendants overstated Revita's efficacy, concealing alleged operational issues at clinical sites in the REMAIN-1 Midpoint Cohort that compromised result integrity.\n\nThe release is a plaintiff-firm solicitation seeking lead plaintiffs before an October 20, 2026 deadline; it contains no new issuer disclosure.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm class-action solicitation naming GUTS -- suppress; monitor only if a court certifies the class."},"keyFigures":{"customDimensions":{"class_period":"January 13, 2025 to January 29, 2026"}},"quotedText":"Revita was less effective than defendants had led investors to believe, and/or operational issues at one or more of the REMAIN-1 Midpoint Cohort's clinical sites compromised the integrity of its efficacy results","namedEntities":{"people":[{"name":"Joseph E. Levi","role":"Esq., Levi & Korsinsky"},{"name":"Ed Korsinsky","role":"Esq., Levi & Korsinsky"}],"products":["Revita"],"companies":[{"name":"Fractyl Health, Inc.","ticker":"GUTS","relationship":"target of class action"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Levi & Korsinsky announcing a securities class action and seeking lead plaintiffs. No certified class or settlement; this is firm marketing rather than an issuer disclosure."},"tickerRelevance":{"others":[],"primary":"GUTS"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingClaims":"clinical-data-integrity allegations on lead asset Revita"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky announced a securities fraud class action filed against Fractyl Health on behalf of investors who purchased GUTS securities between January 13, 2025 and January 29, 2026.\n\nThe complaint alleges defendants overstated Revita's efficacy, concealing alleged operational issues at clinical sites in the REMAIN-1 Midpoint Cohort that compromised result integrity.\n\nThe release is a plaintiff-firm solicitation seeking lead plaintiffs before an October 20, 2026 deadline; it contains no new issuer disclosure.","key_figures":{"customDimensions":{"class_period":"January 13, 2025 to January 29, 2026"}},"named_entities":{"people":[{"name":"Joseph E. Levi","role":"Esq., Levi & Korsinsky"},{"name":"Ed Korsinsky","role":"Esq., Levi & Korsinsky"}],"products":["Revita"],"companies":[{"name":"Fractyl Health, Inc.","ticker":"GUTS","relationship":"target of class action"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-03T22:50:05.580Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingClaims":"clinical-data-integrity allegations on lead asset Revita"}},"durationMs":4689,"modelName":"glm-5.3-flashx"}}